Evidence map›Paper›PMID 35975122›Full record

ArticleClinical pharmacology : advances and applications2022

Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response.

Filip Stefanovic, Andres Gomez-Caminero, David M Jacobs, Poornima Subramanian, Igor Puzanov, Maya R Chilbert, Steven G Feuerstein, Yan Yatsynovich, Benjamin Switzer, Jerome J Schentag

Open access · goldAbstract read
In one paragraph

Article in Clinical pharmacology : advances and applications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Filip StefanovicDepartment of Biomedical Engineering, University at Buffalo School of Engineering and Applied Sciences, Buffalo, NY, USA.
Andres Gomez-CamineroWorldwide Health Economic and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA.
David M JacobsCPL Associates LLC, Buffalo, NY, USA.
Poornima SubramanianCPL Associates LLC, Buffalo, NY, USA.ORCID 0000-0002-6449-6549
Igor PuzanovDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Maya R ChilbertDepartment of Pharmacy Practice, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA.ORCID 0000-0003-3183-5214
Steven G FeuersteinDepartment of Pharmacy Practice, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA.
Yan YatsynovichDepartment of Medicine, University at Buffalo Jacobs School of Medicine, Buffalo, NY, USA.
Benjamin SwitzerDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Jerome J SchentagCPL Associates LLC, Buffalo, NY, USA.
Roswell Park Comprehensive Cancer Center · USUniversity at Buffalo, State University of New York · USBristol-Myers Squibb (United States) · USKettering Medical Center · US

Funding

Integrative Informatics Approach to Predict Readmissions and Improve Outcomes in COPDK23HL153582 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI JACOBS, DAVID · 2021 to 2025
$962k
NHLBI NIH HHS K23 HL153582
6 · The paper itself

Abstract

Background: Serious but rare side effects associated with immunotherapy pose a difficult problem for regulators and practitioners. Immune checkpoint inhibitors (ICIs) have come into widespread use in oncology in recent years and are associated with rare cardiotoxicity, including potentially fatal myocarditis. To date, no comprehensive model of myocarditis progression and outcomes integrating time-series based laboratory and clinical signals has been constructed. In this paper, we describe a time-series neural net (NN) model of ICI-related myocarditis derived using supervised machine learning. Methods: We extracted and modeled data from electronic medical records of ICI-treated patients who had an elevation in their troponin. All data collection was performed using an electronic case report form, with approximately 300 variables collected on as many occasions as available, yielding 6000 data elements per patient over their clinical course. Key variables were scored 0-5 and sequential assessments were used to construct the model. The NN model was developed in MatLab and applied to analyze the time course and outcomes of treatments. Results: We identified 23 patients who had troponin elevations related to their ICI therapy, 15 of whom had ICI-related myocarditis, while the remaining 8 patients on ICIs had other causes for troponin elevation, such as myocardial infarction. Our model showed that troponin was the most predictive biomarker of myocarditis, in line with prior studies. Our model also identified early and aggressive use of steroid treatment as a major determinant of survival for cases of grade 3 or 4 ICI-related myocarditis. Conclusion: Our study shows that a supervised learning NN can be used to model rare events such as ICI-related myocarditis and thus provide clinical insight into drivers of progression and treatment outcomes. These findings direct attention to early detection biomarkers and clinical symptoms as the best means of implementing early and potentially life-saving steroid treatment.

Indexed as

checkpoint inhibitordose and timingmyocarditisNN modelingsteroid response

Identifiers

PMID35975122
PMCPMC9376002
OpenAlexW4292159135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.